Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
-
Patent number: 8362226Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: GrantFiled: June 14, 2012Date of Patent: January 29, 2013Assignee: Battelle Energy Alliance, LLCInventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
-
Patent number: 8357513Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: February 15, 1994Date of Patent: January 22, 2013Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8357535Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).Type: GrantFiled: June 6, 2008Date of Patent: January 22, 2013Assignee: Merck Serono SAInventors: Michel Kobr, Philippe Dupraz
-
Patent number: 8354517Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: GrantFiled: September 20, 2011Date of Patent: January 15, 2013Assignee: Battelle Energy Alliance, LLCInventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
-
Patent number: 8354571Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.Type: GrantFiled: December 22, 2008Date of Patent: January 15, 2013Assignee: Pioneer Hi Bred International IncInventors: Andre R. Abad, Hua Dong, Sue B. Lo, Xiaomei Shi
-
Patent number: 8354251Abstract: The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein.Type: GrantFiled: December 30, 2004Date of Patent: January 15, 2013Assignee: KaloBios Pharmaceuticals, Inc.Inventors: Christopher Robert Bebbington, Bo Yu
-
Patent number: 8350020Abstract: Provided are mRNA translational enhancer elements (TEEs), e.g., SEQ ID NOs:1-35. Also provided are translational enhancer polynucleotides that comprise one or more of the specific TEEs exemplified herein or their variants, homologs or functional derivatives. Further provided are expression vectors comprising such TEEs or translational enhancer polynucleotides, as well as host cells and expression systems that harbor such vectors.Type: GrantFiled: December 11, 2008Date of Patent: January 8, 2013Assignee: The Scripps Research InstituteInventors: Vincent P. Mauro, Gerald M. Edelman, Wei Zhou
-
Patent number: 8338137Abstract: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.Type: GrantFiled: March 19, 2007Date of Patent: December 25, 2012Assignee: Sanofi Pasteur S.A.Inventors: Bachra Rokbi, Claude Meric, Noelle Mistretta, Philippe Talaga, Olivier Adam
-
Patent number: 8338156Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: June 18, 2010Date of Patent: December 25, 2012Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8338171Abstract: Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.Type: GrantFiled: August 12, 2010Date of Patent: December 25, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Bethany Swencki-Underwood, Michael Naso
-
Patent number: 8338385Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: GrantFiled: October 20, 2010Date of Patent: December 25, 2012Assignee: ViroMed Co., Ltd.Inventors: Jong-Mook Kim, Woong Hahn
-
Patent number: 8329465Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.Type: GrantFiled: January 6, 2011Date of Patent: December 11, 2012Assignee: Baxter Innovations GmbHInventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
-
Patent number: 8323928Abstract: Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.Type: GrantFiled: March 24, 2006Date of Patent: December 4, 2012Assignee: PIN Pharma, Inc.Inventor: David I. Cohen
-
Publication number: 20120301923Abstract: The present disclosure provides systems and methods of using a semipermeable membrane in a dialysis fermenter as a separation layer between a cell-containing liquid culture medium and a non-cell-containing dialysis medium. In some embodiments, the semipermeable membrane may have a molecular cut-off of 15 kDa to 50 kDa. The instant disclosure also provides a dialysis fermenter with compartments for cell-containing culture medium, non-cell-containing nutrient solution as well as an exchange unit having a semipermeable membrane, wherein mass transfer takes place between the culture medium and the dialysis medium by means of diffusion and/or ultrafiltration. Methods for culturing cells are also disclosed.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Artur Hoffmann, Max Lechner, Christoph Reese
-
Publication number: 20120301894Abstract: Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.Type: ApplicationFiled: February 17, 2012Publication date: November 29, 2012Applicant: Life Technologies CorporationInventors: Brian AGNEW, Kyle R. Gee, Tamara G. Nyberg
-
Patent number: 8318457Abstract: The present invention relates to nucleic acid molecules comprising a nucleic acid sequence coding for the ?- and the ?-chain of the human follicle stimulating hormone (FSH), respectively, which has been modified with respect to the codon usage in CHO cells. The present invention further relates to a recombinant nucleic acid molecule comprising such nucleic acid sequences and host cells containing such recombinant nucleic acid molecules, as well as their use in the production of recombinant human FSH. Finally, the present invention also relates to a method for producing host cells expressing human follicle stimulating hormone by transfecting cells in suspension culture under serum-free conditions with the recombinant nucleic acid molecule of the present invention.Type: GrantFiled: June 27, 2008Date of Patent: November 27, 2012Assignee: BioGeneriX AGInventors: Stefan Arnold, Nanni Jelinek
-
Patent number: 8309326Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.Type: GrantFiled: April 15, 2011Date of Patent: November 13, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer
-
Patent number: 8299323Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, or the nucleotide sequence set forth in SEQ ID NO:1, as well as variants thereof.Type: GrantFiled: February 7, 2010Date of Patent: October 30, 2012Assignee: Athenix CorporationInventors: Nadine Carozzi, Tracy Hargiss, Michael G. Koziel, Nicholas B. Duck, Brian Carr
-
Patent number: 8298790Abstract: Disclosed is a method for coexpressing IL-12 (interleukin-12) and IL-23 (interleukin-23), which comprises the steps of: (a) preparing vectors comprising monocistronic expression constructs of each of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit, or preparing a vector comprising a polycistronic expression construct of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit; (b) transforming the expression constructs into a host cell; and (c) culturing the transformed host cell to obtain IL-12 and IL-23, a vector for coexpressing IL-12 and IL-23, and a pharmaceutical anti-tumor composition comprising the vectors.Type: GrantFiled: January 17, 2008Date of Patent: October 30, 2012Inventor: Chae-Ok Yun
-
Patent number: 8293500Abstract: The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.Type: GrantFiled: March 22, 2007Date of Patent: October 23, 2012Assignee: Viral Logic Systems Technology Corp.Inventors: Steven Wiley, Craig A Smith, Ajamete Kaykas
-
Patent number: 8293876Abstract: The present invention relates to a method for obtaining highly purified hydrophobic proteins from cells by extraction using a buffer containing a detergent and removal of said detergent by hydroxyapatite (HA) column chromatography.Type: GrantFiled: February 19, 2008Date of Patent: October 23, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Tauer Christa, Mitterer Artur
-
Patent number: 8288125Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.Type: GrantFiled: April 15, 2011Date of Patent: October 16, 2012Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer
-
Publication number: 20120258498Abstract: High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from Glarea lozoyensis, and deposited in CGMCC with the accession number of CGMCC 2933. The preparation method concludes following steps: (a) mixing the culture media of Glarea lozoyensis strain ATCC 20957 with nitrosoguanidine, and obtaining mixture a; (b) mixing lywallzyme with the mixture a, and obtaining protoplasts; (c) regenerating the protoplasts, and obtaining single clones; and (d) culturing the single clones, then obtaining the mutant strain. This fungus strain has stable genetic and producing property, produces little impurities in fermentation, and is suitable to be used in industry.Type: ApplicationFiled: September 28, 2009Publication date: October 11, 2012Applicant: SHANGHAI TECHWELL BIOPHARMACEUTICAL CO., LTD.Inventors: Jing Xu, Yi Chen, Xiaoming Ji, Xiaoliang Gao, Shidong Liu, Zhaoli Zhang
-
Patent number: 8283138Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.Type: GrantFiled: August 17, 2009Date of Patent: October 9, 2012Assignee: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Konrad Miatkowski, Werner Meier
-
Patent number: 8278270Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.Type: GrantFiled: July 1, 2011Date of Patent: October 2, 2012Assignees: Kringle Pharma Inc., Osaka UniversityInventors: Toshikazu Nakamura, Kunio Matsumoto, Kazuhiro Fukuta, Kiichi Adachi, Daichika Hayata
-
Patent number: 8278424Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: April 26, 2011Date of Patent: October 2, 2012Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20120231504Abstract: A septum is positioned within a disposable vessel and defines a lower chamber and an upper chamber. The septum includes a plurality of apertures that provide fluid communication between the upper chamber and lower chamber. Compressed gas is introduced in the lower chamber to produce fine bubbles rising up throughout the vessel to produce a mixing and gasification needed for the growth of a biological culture and manufacture of a biological product in a nutrient medium. Adding a binding resin to the upper chamber allows harvesting, separation and purification of biological products in the reactor as a single unit operation.Type: ApplicationFiled: September 3, 2011Publication date: September 13, 2012Applicant: Therapeutic Proteins Inc.Inventor: Sarfaraz K. Niazi
-
Patent number: 8263750Abstract: A method for purifying a protein using Protein A chromatography comprising a) absorbing the protein to Protein A immobilized on a solid support; b) removing contaminants by washing the immobilized Protein A containing the absorbed protein with a buffer comprising one or more chaotropic agents in combination with one or more hydrophobic modifiers and having a pH of at least 7.0; and c) eluting the protein from the Protein A immobilized on the solid support.Type: GrantFiled: March 16, 2007Date of Patent: September 11, 2012Assignee: Amgen Inc.Inventors: Abhinav A. Shukla, Peter Hinckley
-
Patent number: 8257947Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: January 30, 2009Date of Patent: September 4, 2012Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Patent number: 8252972Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.Type: GrantFiled: January 6, 2010Date of Patent: August 28, 2012Assignee: Pioneer Hi Bred International IncInventors: Andre R. Abad, Hua Dong, Deirdre M. Kapka-Kitzman, Sue B. Lo, Xiaomei Shi
-
Publication number: 20120214192Abstract: The present invention provides a method for producing an antigen-specific B cell population comprising IgG-positive B cells specific to a specific antigen, the method comprising: culturing IgG-positive B cells together with the specific antigen in the presence of IL-21, while conferring stimulation to the IgG-positive B cells via CD40, a BAFF receptor and Fas; and screening for antigen-specific B cells specific to the specific antigen to obtain an antigen-specific B cell population comprising the IgG-positive B cells specific to the specific antigen.Type: ApplicationFiled: October 25, 2010Publication date: August 23, 2012Applicant: Tokyo University of Science Educational Foundation Administrative OrganizationInventors: Daisuke Kitamura, Takuya Nojima
-
Patent number: 8241872Abstract: A microorganism which produces compounds useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, such as mycotic sinusitis, is provided. The present inventors have conducted intensive studies on naturally-occurring microorganisms as a research for antifungal compounds, and found a fungus Acremonium persicinum which produces cyclic compounds having a potent antifungal activity and useful as a medicament, particularly an antifungal agent, and the present invention was completed.Type: GrantFiled: March 13, 2009Date of Patent: August 14, 2012Assignee: Astellas Pharma Inc.Inventors: Ikuko Nakamura, Koji Yoshikawa, Teruhisa Masaki, Ryuichi Kanasaki, Neelam Shahab
-
Patent number: 8232100Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: GrantFiled: July 21, 2010Date of Patent: July 31, 2012Assignee: Isis Innovation LimitedInventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
-
Patent number: 8227212Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.Type: GrantFiled: February 10, 2004Date of Patent: July 24, 2012Assignee: Shire Human Genetic Therapies, Inc.Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Maria Pia Cosma, Andrea Ballabio
-
Patent number: 8221998Abstract: This present invention relates to the use of the B1 domain of Protein G as an epitope tag for over-expression of proteins in mammalian cells.Type: GrantFiled: May 19, 2006Date of Patent: July 17, 2012Assignee: GlaxoSmithKline LLCInventors: Kyung Oh Johanson, John J. Trill
-
Patent number: 8216805Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).Type: GrantFiled: February 4, 2010Date of Patent: July 10, 2012Assignee: Genentech, Inc.Inventors: Paul J. Carter, Leonard G. Presta, John B. Ridgway
-
Patent number: 8211670Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: May 24, 2011Date of Patent: July 3, 2012Assignee: ZymoGenetics, Inc.Inventors: Bruce L. Zamost, Robert M. Dedinsky
-
Patent number: 8206947Abstract: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.Type: GrantFiled: November 8, 2006Date of Patent: June 26, 2012Assignee: Incyte CorporationInventors: Y. Tom Tang, Preeti G. Lal, Jennifer L. Jackson, Henry Yue, Karl J. Guegler, Neil C. Corley, Olga Bandman, Chandra S. Arvizu, Gina A. Gorgone Simone, Matthew R. Kaser, Mariah R. Baughn, Janice K. Au-Young
-
Publication number: 20120156726Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.Type: ApplicationFiled: August 19, 2010Publication date: June 21, 2012Inventors: Michael Schraeml, Leopold Von Proff
-
Publication number: 20120149062Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.Type: ApplicationFiled: February 16, 2012Publication date: June 14, 2012Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
-
Patent number: 8193323Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 18, 1995Date of Patent: June 5, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8192955Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: May 25, 1994Date of Patent: June 5, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8183207Abstract: Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.Type: GrantFiled: November 25, 2009Date of Patent: May 22, 2012Assignee: Five Prime Therapeutics, Inc.Inventors: Haishan Lin, Li Long
-
Patent number: 8178107Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 18, 1995Date of Patent: May 15, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8173398Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: September 23, 2011Date of Patent: May 8, 2012Assignee: Femta Pharmaceuticals, Inc.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Publication number: 20120107452Abstract: This invention relates to an aeration system comprising an aeration section, a degassing section and optionally an additional section. This invention also relates to a horizontal photobioreactor comprising the aeration system. This invention further relates to methods of using the photobioreactors.Type: ApplicationFiled: April 16, 2010Publication date: May 3, 2012Inventors: Andreas Meiser, Lawrence A. Walmsley
-
Publication number: 20120100576Abstract: The present invention pertains to a system for culturing cells comprising a culturing bag and a continuous flow centrifuge wherein the cells are continuously separated from the supernatant and are recycled into the culturing bag. Further provided are methods for culturing cells and for producing a biological substance using the device for culturing cells, and the use of a bag for culturing cells in said device or said methods. In particular, a perfusion system for culturing cells is provided wherein the wave technology for culturing cells is combined with continuous flow centrifugation for separating the medium from the cells.Type: ApplicationFiled: July 8, 2010Publication date: April 26, 2012Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Rainer Stahn, Annett Hillemann
-
Publication number: 20120100236Abstract: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.Type: ApplicationFiled: October 24, 2011Publication date: April 26, 2012Applicant: MARRONE BIO INNOVATIONS, INC.Inventors: Ratnakar Asolkar, Huazhang Huang, Marja Koivunen, Pamela Marrone
-
Patent number: 8163886Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.Type: GrantFiled: December 20, 2007Date of Patent: April 24, 2012Assignee: EMD Millipore CorporationInventor: Wilson Moya